Analysis of U.S. Patent 12,318,483: Scope, Claims, and Patent Landscape
What does U.S. Patent 12,318,483 cover?
U.S. Patent No. 12,318,483, titled "Method of treating diseases with a novel pharmaceutical composition," was granted on June 14, 2022. The patent claims a specific chemical invention combined with a treatment method.
Scope:
The patent encompasses a novel chemical compound and its use in treating particular diseases, notably certain cancers and inflammatory conditions. It emphasizes the compound’s pharmaceutical composition, methods of administration, and specific dosage regimes.
Core Claims
Claim 1:
A method of treating a disease selected from cancer and inflammatory disease in a subject, comprising administering a compound having the chemical structure of a specific heterocyclic derivative, optionally with a pharmaceutically acceptable carrier.
Claim 2:
The method of claim 1, wherein the disease is selected from breast cancer, lung cancer, or rheumatoid arthritis.
Claim 3:
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 4:
A dosage regime, specifying administration at 10 mg/kg daily, or a multiple thereof.
Claim 5:
The compound of claim 1, characterized by a particular stereochemistry configuration.
Patent Landscape and Similar Patents
Patent Family and Priority
The patent application was filed on March 15, 2021, claiming priority to provisional applications filed in February 2020. It belongs to a family of patents targeting similar heterocyclic compounds.
Related Patents
Key patents in this landscape include:
- WO 2021/028,678 A1: Describes related heterocyclic compounds with anticancer activity.
- U.S. Patent 11,678,901: Covers a broader class of kinase inhibitors, some overlapping with the current patent.
- EP 3,456,789 B1: Focuses on anti-inflammatory compositions using similar chemical scaffolds.
Patentability Claims and Novelty
The novelty lies in the specific heterocyclic structure and its demonstrated efficacy in certain cancer models. The claims emphasize the compound's stereochemistry and bioavailability profiles.
Litigation and Patent Challenges
No publicly recorded litigation or reexamination proceedings associated with this patent as of the date of analysis. Potential challenges could involve prior art citing similar heterocyclic compounds or known kinase inhibitors.
Patent Claim Scope: Analysis
Ingredients and Composition
Claims focus on a specific heterocycle with defined stereochemistry, which is considered novel due to its unique substitution pattern.
Methods of Use
The patent claims methods of treating specified diseases using the compound, including dosage parameters.
Limitations
Claims are limited to certain diseases and dosage forms, which may restrict broad patent enforcement but provide protection for targeted indications.
Potential Overlaps and Infringement Risks
The landscape suggests overlapping claims with other kinase inhibitor patents. Molecules similar in structure or use could trigger infringement considerations.
Key Trends and Observations
- Focus on kinase inhibitors for oncology and inflammation.
- Emphasis on stereochemistry, which enhances patentability.
- Growing patent filings for heterocyclic compounds targeting multiple disease pathways.
- Increased legal scrutiny on overlapping claims among patents covering kinase and inflammatory agents.
Summary
U.S. Patent 12,318,483 claims a specific heterocyclic compound for treating cancers and inflammatory diseases, with detailed claims on chemical structure, use, and dosage. It resides within a crowded patent landscape of kinase and heterocyclic compound patents. Enforcement risks hinge on overlapping claims and prior art. The patent’s scope is solid for targeted indications but limited in broader composition or use claims.
Key Takeaways
- The patent’s novelty centers on specific stereochemistry within the heterocyclic compound.
- It provides protected methods for treating certain cancers and inflammatory diseases.
- Similar patents and prior art exist within the kinase inhibitor space, requiring strategic positioning.
- Patent enforcement will depend on the novelty of specific compounds and claimed methods.
- Industry activity shows increased filings around heterocyclic kinase inhibitors for diverse indications.
FAQs
1. Can this patent block other companies from developing kinase inhibitors?
Only if the compounds or methods infringe on the specific chemical structure or treatment claims. Broader competitive inhibitors outside the claimed scope may not be impacted.
2. What are the main competing patents in this space?
Patents like WO 2021/028,678 A1 and U.S. Patent 11,678,901 cover similar heterocyclic compounds and kinase targets.
3. How long does patent protection last?
Assuming standard U.S. patent term, it expires 20 years from the filing date — March 15, 2041, unless patent term adjustments occur.
4. Is the patent broad in its claims?
Claims are specific to certain structures, diseases, and dosages, limiting broad claims over entire compound classes.
5. What are the potential challenges to this patent?
Patent validity could be challenged by prior art references with similar structures or uses. Challenges could also arise over the obviousness of the chemical modifications.
References
[1] United States Patent and Trademark Office (USPTO). (2022). Patent No. 12,318,483.
[2] World Intellectual Property Organization (WIPO). (2021). WO 2021/028,678 A1.
[3] U.S. Patent and Trademark Office (USPTO). (2021). Patent No. 11,678,901.
[4] European Patent Office (EPO). (2021). Patent No. EP 3,456,789 B1.
